3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms, Male
1
Interventions
Doxorubicin
13
Specimen Handling
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
Cyclophosphamide
9
X-Rays
7
Ifosfamide
7
Radiotherapy
6
Phantoms, Imaging
6
Gemcitabine
6
liposomal doxorubicin
5
Nivolumab
5
tazemetostat
4
palbociclib
4
fludarabine
4
atezolizumab
4
Temozolomide
4
Radiation
4
Nuclear Medicine Department, Hospital
4
Irinotecan
4
larotrectinib
3
cabozantinib
3
Surveys and Questionnaires
3
Ipilimumab
3
Carboplatin
3
Bevacizumab
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Genetic Counseling
×
90 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled